WO2023241659A1 - Methods of treating lymphoma using anti-tigit antibodies - Google Patents
Methods of treating lymphoma using anti-tigit antibodies Download PDFInfo
- Publication number
- WO2023241659A1 WO2023241659A1 PCT/CN2023/100462 CN2023100462W WO2023241659A1 WO 2023241659 A1 WO2023241659 A1 WO 2023241659A1 CN 2023100462 W CN2023100462 W CN 2023100462W WO 2023241659 A1 WO2023241659 A1 WO 2023241659A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- chain variable
- variable region
- tigit
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 206010025323 Lymphomas Diseases 0.000 title description 11
- 230000027455 binding Effects 0.000 claims abstract description 92
- 239000000427 antigen Substances 0.000 claims abstract description 70
- 108091007433 antigens Proteins 0.000 claims abstract description 70
- 102000036639 antigens Human genes 0.000 claims abstract description 70
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract description 66
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims abstract description 66
- 239000012634 fragment Substances 0.000 claims abstract description 63
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims abstract description 50
- 238000011282 treatment Methods 0.000 claims description 38
- 229960004641 rituximab Drugs 0.000 claims description 32
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 16
- 102000049823 human TIGIT Human genes 0.000 claims description 16
- 238000002512 chemotherapy Methods 0.000 claims description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 11
- 102000048362 human PDCD1 Human genes 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 229960004528 vincristine Drugs 0.000 claims description 7
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 7
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 229960003347 obinutuzumab Drugs 0.000 claims description 6
- 229960004618 prednisone Drugs 0.000 claims description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 6
- 229960005267 tositumomab Drugs 0.000 claims description 6
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract description 36
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 230000028993 immune response Effects 0.000 abstract description 5
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 229940068798 ociperlimab Drugs 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 29
- 229950007123 tislelizumab Drugs 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 18
- 108010074708 B7-H1 Antigen Proteins 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 125000000539 amino acid group Chemical group 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 11
- 230000013595 glycosylation Effects 0.000 description 11
- 238000006206 glycosylation reaction Methods 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 7
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 102100029740 Poliovirus receptor Human genes 0.000 description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- -1 e.g. Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000010380 tumor lysis syndrome Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000006051 NK cell activation Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012893 effector ligand Substances 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108010048507 poliovirus receptor Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 229940125556 BGB-A1217 Drugs 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 description 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 108091008033 coinhibitory receptors Proteins 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 101150023212 fut8 gene Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229950009416 polatuzumab vedotin Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 229950007133 tiragolumab Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940020434 vibostolimab Drugs 0.000 description 1
- 229950007153 zanubrutinib Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Definitions
- the present application relates to antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains) in combination with anti-PD1 antibodies and/or anti-CD20 antibodies for the treatment of lymphoma such as diffuse large B cell lymphoma (DLCBL) .
- TIGIT T cell immunoreceptor with Ig and ITIM domains
- DLCBL diffuse large B cell lymphoma
- TIGIT T cell immunoglobulin and ITIM domain
- TIGIT T cell immunoglobulin and ITIM domain
- TIGIT The genes and cDNAs coding for TIGIT were cloned and characterized in mouse and human.
- Full length human TIGIT has a sequence of 244 amino acids (SEQ ID NO: 1) in length, in which the first 21 amino acids consist of a signal peptide.
- the amino acid sequence of the mature human TIGIT contains 223 amino acid (aa) residues (NCBI accession number: NM_173799) .
- the extracellular domain (ECD) of mature human TIGIT consists of 120 amino acid residues (SEQ ID NO: 2, corresponding to amino acids 22-141 of SEQ ID NO: 1) with a V-type Ig-like domain (corresponding to amino acids 39-127 of SEQ ID NO: 1) , followed by a 21 aa transmembrane sequence, and an 82 aa cytoplasmic domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) (Yu X, et al. 2009 Nat. Immunol, 10: 48-57; Stengel KF, et al. 2012 PNAS 109: 5399-04) .
- ITIM immunoreceptor tyrosine-based inhibitory motif
- Monoclonal antibodies that target either PD1 or PD-L1 can block this interaction and boost the immune response against cancer cells. These antibodies have been shown to be helpful in treating several types of cancer, including melanoma of the skin, non-small cell lung cancer (NSCLC) , kidney cancer, bladder cancer, head and neck cancers, and Hodgkin lymphoma. Cancer cells in most non-responders to single-agent checkpoint inhibitors escape through innate mechanisms that allow the cancer cells to grow and survive. As a result, disease progresses at a rate consistent with the natural history. However, unlike intrinsic resistance, late relapses are now emerging in patients with prior clinical benefit after longer follow-up of clinical trials, suggesting the emergence of acquired resistance (Jenkins et al., Br. J. Cancer 118, 9-16 2018) .
- Anti-CD20 antibodies for example, rituximab can be responsible for rapidly killing tumor targets via Fc ⁇ R mediated ADCC or antibody dependent cellular phagocytosis (ADCP) , a short-term process mediated by natural killer cells and myeloid effector cells from innate immune system (Taylor and Lindorfer, Curr Opin Immunol. 2008; 20 (4) : 444-449; Minard-Colin et al., Blood. 2008; 112 (4) : 1205-1213) . Studies also reveal that the therapeutic function and long-term immune memory of anti-CD20 antibodies require active crosstalk with adaptive immunity.
- ADCP antibody dependent cellular phagocytosis
- lymphoma patients evidence in lymphoma patients suggests that rituximab can induce a strong antitumor vaccinal effect by priming antitumor T cell responses, resulting in durable response (Cartron et al., Blood. 2004; 104 (9) : 2635-2642) .
- Using a murine lymphoma model to express human CD20 CD4+ and CD8+ T cells are demonstrated to be required for anti CD20 mAb mediated long term memory immune response (Abes et al., Blood.
- Diffuse large B-cell lymphoma is an aggressive and heterogeneous disease with a variable clinical outcome (Susanibar-Adaniya et al., Am J Hematol. 2021; 96 (5) : 617-629. ) and is the most common subtype of aggressive non-Hodgkin lymphomas (NHL) in the Western countries, accounting for around 31%of NHL cases in adults. There were 544, 352 new cases of NHL and 259, 793 deaths resulting from this disease worldwide in 2020 (Sung et al., CA Cancer J Clin. 2021; 71 (3) : 209-249) .
- the incidence rate for DLBCL is approximately 6.9 cases per 100,000 person-years (Teras et al., CA Cancer J Clin. 2016 Nov 12; 66 (6) : 443-459) .
- Two locally retrospective studies for NHL distributions in China showed that DLBCL made up about 29.1%and 40.9%of NHL, respectively (Liu et al., Asian Pac J Cancer Prev.
- the present disclosure is directed methods of diffuse large B-cell lymphoma (DLBCL) treatment, administering anti-TIGIT antibodies in combination with anti-PD1 antibodies and/or anti-CD20 antibodies.
- DLBCL diffuse large B-cell lymphoma
- a method of diffuse large B-cell lymphoma (DLBCL) treatment comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-PD1 antibody or antigen binding fragment thereof.
- DLBCL diffuse large B-cell lymphoma
- the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
- HCDR Heavy Chain Complementarity Determining Region
- LCDR Light Chain Complementarity Determining Region
- the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
- the anti-PD1 antibody comprises an antibody or an antigen binding fragment thereof which specifically binds human PD1, and comprises: a heavy chain variable region that comprises: a HCDR1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14; and a light chain variable region that comprises LCDR1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17.
- the anti-PD1 antibody or antigen binding fragment thereof which specifically binds human PD1 and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 18 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 19.
- anti-PD1 antibody comprises an IgG4 constant domain comprising SEQ ID NO: 20.
- the anti-TIGIT antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab') 2 fragments.
- the anti-PD1 antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab') 2 fragments.
- a method of diffuse large B-cell lymphoma (DLBCL) treatment comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-CD20 antibody or antigen binding fragment thereof.
- DLBCL diffuse large B-cell lymphoma
- the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
- HCDR Heavy Chain Complementarity Determining Region
- LCDR Light Chain Complementarity Determining Region
- the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
- the method wherein the anti-CD20 antibody is Rituximab (Rituxan) , Britumomab (Zevalin) , Tositumomab (Bexxar) or Obinutuzumab (Gazyva) .
- the method wherein the anti-CD20 antibody is Rituximab (Rituxan) .
- the method further comprising the administration of chemotherapy.
- the method wherein the chemotherapy is cyclophosphamide, doxorubicin, vincristine, and prednisone.
- the method wherein the anti-PD1 antibody is dosed at 200mg every three weeks.
- the method wherein the anti-TIGIT antibody is dosed at a range of 50mg-900mg.
- the method wherein the anti-TIGIT antibody is dosed at 50 mg every three weeks.
- the method wherein the anti-TIGIT antibody is dosed at 150 mg every three weeks.
- the method wherein the anti-TIGIT antibody is dosed at 450 mg every three weeks.
- the method wherein the anti-TIGIT antibody is dosed at 900 mg every three weeks.
- a method of diffuse large B-cell lymphoma (DLBCL) treatment comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-CD20 antibody or antigen binding fragment thereof and an effective amount of an anti-PD1 antibody.
- DLBCL diffuse large B-cell lymphoma
- the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
- HCDR Heavy Chain Complementarity Determining Region
- LCDR Light Chain Complementarity Determining Region
- the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
- the anti-PD1 antibody comprises an antibody or an antigen binding fragment thereof which specifically binds human PD1, and comprises: a heavy chain variable region that comprises: a HCDR1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14; and a light chain variable region that comprises LCDR1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17.
- the anti-PD1 antibody or antigen binding fragment thereof which specifically binds human PD1 and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 18 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 19.
- the method further comprising the administration of chemotherapy.
- the method wherein the chemotherapy is cyclophosphamide, doxorubicin, vincristine, and prednisone.
- Figure 1 is a graphical representation of the therapeutics, their dosages and cohorts
- amino acids are commonly known in the art and exemplarily shown in the table below. Generally, a conservative amino acid substitution means that an amino acid residue is replaced by another amino acid residue having a similar side chain.
- TIGIT includes various mammalian isoforms, e.g., human TIGIT, orthologs of human TIGIT, and analogs comprising at least one epitope within TIGIT.
- the amino acid sequence of TIGIT, e.g., human TIGIT, and the nucleotide sequence encoding the same, is known in the art (see Genbank AAI01289) .
- PD1 or “Programmed cell death protein 1” is a receptor that delivers inhibitory signals upon binding to ligands CD274/PD-L1 and CD273/PD-L2.
- the amino acid sequence of human PD1 is known in the art and can be found at accession number NP_005009 (Genbank) .
- CD-20 or “B-lymphocyte surface antigen B1” is a B-lymphocyte-specific membrane protein that aids in the regulation of cellular calcium influx.
- the amino acid of CD20 is set forth in Genbank accession number NP_068769.
- administering when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, mean contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid.
- Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.
- administration or “treatment” also includes in vitro and ex vivo treatments, e.g., of a cell, by a reagent, diagnostic, binding compound, or by another cell.
- subject herein refers to any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, rabbit) and most preferably a human.
- antibody herein is used in the broadest sense and specifically covers antibodies (including full length monoclonal antibodies) and antibody fragments so long as they recognize antigen, e.g., TIGIT.
- An antibody is usually monospecific, but may also be described as idiospecific, heterospecific, or polyspecific.
- Antibody molecules bind by means of specific binding sites to specific antigenic determinants or epitopes on antigens.
- the term “monoclonal antibody” or “mAb” or “Mab” herein means a population of substantially homogeneous antibodies, i.e., the antibody molecules comprised in the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts.
- conventional (polyclonal) antibody preparations typically include a multitude of different antibodies having different amino acid sequences in their variable domains, particularly their complementarity determining regions (CDRs) , which are often specific for different epitopes.
- CDRs complementarity determining regions
- the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method.
- Monoclonal antibodies may be obtained by methods known to those skilled in the art. See, for example Kohler G et al., Nature 1975 256: 495-497; U.S. Pat. No. 4,376,110; Ausubel FM et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY 1992; Harlow E et al., ANTIBODIES: A LABORATORY MANUAL, Cold spring Harbor Laboratory 1988; and Colligan JE et al., CURRENT PROTOCOLS IN IMMUNOLOGY 1993.
- the mAbs disclosed herein may be of any immunoglobulin class including IgG, IgM, IgD, IgE, IgA, and any subclass thereof.
- a hybridoma producing a mAb may be cultivated in vitro or in vivo.
- High titers of mAbs can be obtained by in vivo production where cells from the individual hybridomas are injected intraperitoneally into mice, such as pristine-primed Balb/c mice to produce ascites fluid containing high concentrations of the desired mAbs.
- MAbs of isotype IgM or IgG may be purified from such ascites fluids, or from culture supernatants, using column chromatography methods well known to those of skill in the art.
- the basic antibody structural unit comprises a tetramer.
- Each tetramer includes two identical pairs of polypeptide chains, each pair having one “light chain” (about 25 kDa) and one “heavy chain” (about 50-70 kDa) .
- the amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- the carboxy-terminal portion of the heavy chain may define a constant region primarily responsible for effector function.
- human light chains are classified as kappa and lambda light chains.
- human heavy chains are typically classified as ⁇ , ⁇ , ⁇ , ⁇ , or ⁇ , and define the antibody's isotypes as IgA, IgD, IgE, IgG, and IgM, respectively.
- the variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids.
- variable regions of each light/heavy chain (VL/VH) pair form the antibody binding site.
- an intact antibody has two binding sites.
- the two binding sites are, in general, the same.
- variable domains of both the heavy and light chains comprise three hypervariable regions, also called “complementarity determining regions (CDRs) ” , which are located between relatively conserved framework regions (FR) .
- the CDRs are usually aligned by the framework regions, enabling binding to a specific epitope.
- both light and heavy chain variable domains sequentially comprise FR-1 (or FR1) , CDR-1 (or CDR1) , FR-2 (FR2) , CDR-2 (CDR2) , FR-3 (or FR3) , CDR-3 (CDR3) , and FR-4 (or FR4) .
- hypervariable region means the amino acid residues of an antibody that are responsible for antigen-binding.
- the hypervariable region comprises amino acid residues from a “CDR” (i.e., VL-CDR1, VL-CDR2 and VL-CDR3 in the light chain variable domain and VH-CDR1, VH-CDR2 and VH-CDR3 in the heavy chain variable domain) .
- CDR i.e., VL-CDR1, VL-CDR2 and VL-CDR3 in the light chain variable domain and VH-CDR1, VH-CDR2 and VH-CDR3 in the heavy chain variable domain
- CDR CDR
- sequences of Proteins of Immunological Interest 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.
- CDR regions of an antibody by sequence see also Chothia and Lesk (1987) J. Mol. Biol. 196: 901-917 (defining the CDR regions of an antibody by structure) .
- antibody fragment or “antigen-binding fragment” means antigen binding fragments of antibodies, i.e., antibody fragments that retain the ability to bind specifically to the antigen bound by the full-length antibody, e.g., fragments that retain one or more CDR regions.
- antigen binding fragments include, but not limited to, Fab, Fab', F (ab') 2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, e.g., single chain Fv (ScFv) ; nanobodies and multispecific antibodies formed from antibody fragments.
- An antibody that binds to a specified target protein with specificity is also described as specifically binding to a specified target protein. This means the antibody exhibits preferential binding to that target as compared to other proteins, but this specificity does not require absolute binding specificity.
- An antibody is considered “specific” for its intended target if its binding is determinative of the presence of the target protein in a sample, e.g., without producing undesired results such as false positives.
- Antibodies or binding fragments thereof, useful in the present invention will bind to the target protein with an affinity that is at least two-fold greater, preferably at least 10-times greater, more preferably at least 20-times greater, and most preferably at least 100-times greater than the affinity with non-target proteins.
- An antibody herein is said to bind specifically to a polypeptide comprising a given amino acid sequence, e.g., the amino acid sequence of a mature human TIGIT molecule, if it binds to polypeptides comprising that sequence but does not bind to proteins lacking that sequence.
- pH-dependent binding binds to its target/antigen, namely human TIGIT, in a pH-dependent manner.
- the antibody of the present application shows a higher binding affinity and/or binding signal to its antigen at a mild acidic pH, e.g., pH 6.0, which is usually found in tumor microenvironment, as compared to the binding affinity and/or binding signal at physiologic pH, e.g., pH 7.4.
- the methods for determining the binding affinity and/or the intensity of binding signal of the antibody of the present application are well known in the art and include but not limited to surface plasmon resonance (Biacore) or similar technology. More specifically, the antibody of the present application has a K D ratio at pH 7.4/pH 6.0 of greater than 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more, as measured by surface plasmon resonance (Biacore) or similar technology.
- the antibody of the present application has a Rmax (RU) value at pH 6.0 which is at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold higher than the Rmax at pH 7.4 as measured by surface plasmon resonance (Biacore) or similar technology.
- the binding affinity of the antibody can be measured at 25°C or 37°C. Tumor microenvironment has been found to show a relatively more acidic pH than physiological condition or normal tissues.
- the antibody of the present application having above-mentioned pH-dependent binding is advantageous as an anti-TIGIT therapeutic agent for targeting TIGIT-positive lymphocytes in the tumor microenvironment with selectivity and having lower toxicity associated with periphery activation of lymphocytes.
- human antibody herein means an antibody that comprises human immunoglobulin protein sequences only.
- a human antibody may contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell.
- mouse antibody or “rat antibody” means an antibody that comprises only mouse or rat immunoglobulin protein sequences, respectively.
- humanized antibody means forms of antibodies that contain sequences from non-human (e.g., murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin.
- the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
- the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc) , typically that of a human immunoglobulin.
- Fc immunoglobulin constant region
- the prefix “ hum, ” “ hu, ” “Hu” or “h” is added to antibody clone designations when necessary to distinguish humanized antibodies from parental rodent antibodies.
- the humanized forms of rodent antibodies will generally comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions may be included to increase affinity, increase stability of the humanized antibody, or for other reasons.
- cancer or “tumor” herein means or describes the physiological condition in mammals that is typically characterized by unregulated cell growth.
- examples of cancer include but are not limited to, leukemia, lymphoma, diffuse large B-cell lymphoma (DLBCL) and relapsed or refractory DLBCL.
- the antibody of the present application has potential therapeutic uses in controlling viral infections and other human diseases that are mechanistically involved in immune tolerance or ′′exhaustion. ”
- exhaust refers to a process which leads to a depleted ability of immune cells to respond during to a cancer or a chronic viral infection.
- terapéuticaally effective amount refers to the amount of an antibody that, when administered to a subject for treating a disease or a disorder, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or symptom.
- the “therapeutically effective amount” can vary with the antibody, the disease, disorder, and/or symptoms of the disease or disorder, severity of the disease, disorder, and/or symptoms of the disease or disorder, the age of the subject to be treated, and/or the weight of the subject to be treated. An appropriate amount in any given instance can be apparent to those skilled in the art or can be determined by routine experiments.
- the “therapeutically effective amount” refers to the total amount of the active agents comprised in the combination for the effective treatment of a disease, a disorder or a condition.
- the “subject” as used herein is a mammal, e.g., a rodent or a primate, preferably a higher primate, e.g., a human (e.g., a patient having, or at risk of having, a disorder described herein) .
- the present disclosure provides for antibodies, antigen-binding fragments, that specifically bind human TIGIT. Furthermore, the present disclosure provides antibodies that have desirable pharmacokinetic characteristics and other desirable attributes, and thus can be used for the treatment of lymphoma, for example, DLBCL. The present disclosure further provides pharmaceutical compositions comprising the antibodies and methods of making and using such pharmaceutical compositions for the prevention and treatment of DLBCL and associated disorders.
- Anti-TIGIT antibodies are also provided herein and comprise, for example, a heavy chain variable region (VH) comprising the complementarity determining regions (CDRs) : HCDR1 as set forth in SEQ ID NO: 1 , HCDR2 as set forth in SEQ ID NO: 2, and HCDR3 as set forth in SEQ ID NO: 3; and a light chain variable region (VL) comprising: LCDR1 as set forth in SEQ ID NO: 4, LCDR2 as set forth in SEQ ID NO: 5, and LCDR3 as set forth in SEQ ID NO: 6.
- VH heavy chain variable region
- CDRs complementarity determining regions
- Antibodies or antigen-binding fragments of the present disclosure include, but are not limited to, the antibodies or antigen-binding fragments thereof, as described in Table 1 below, which is designated “BGB-A1217” or “Ociperlimab. ”
- PD1 antibodies are also provided herein and comprise, for example, a heavy chain variable region (VH) comprising the complementarity determining regions (CDRs) : HCDR1 as set forth in SEQ ID NO: 12 , HCDR2 as set forth in SEQ ID NO: 13, and HCDR3 as set forth in SEQ ID NO: 14; and a light chain variable region (VL) comprising: LCDR1 as set forth in SEQ ID NO: 15, LCDR2 as set forth in SEQ ID NO: 16, and LCDR3 as set forth in SEQ ID NO: 17.
- VH heavy chain variable region
- CDRs complementarity determining regions
- the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector functions of the antibody.
- one or more amino acids can be replaced with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains the antigen-binding ability of the parent antibody.
- the effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in, e.g., U.S. Pat. Nos. 5,624,821 and 5,648,260, both by Winter et al.
- one or more amino acid residues can be replaced with one or more different amino acid residues such that the antibody has altered C1q binding and/or reduced or abolished complement dependent cytotoxicity (CDC) .
- CDC complement dependent cytotoxicity
- one or more amino acid residues are altered to thereby alter the ability of the antibody to fix complement. This approach is described in, e.g., the PCT Publication WO 94/29351 by Bodmer et al.
- one or more amino acids of an antibody or antigen-binding fragment thereof of the present disclosure are replaced by one or more allotypic amino acid residues, for the IgG1 subclass and the kappa isotype.
- Allotypic amino acid residues also include, but are not limited to, the constant region of the heavy chain of the IgG1, IgG2, and IgG3 subclasses as well as the constant region of the light chain of the kappa isotype as described by Jefferis et al., MAbs. 1: 332-338 (2009) .
- the Fc region is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or to increase the affinity of the antibody for an Fc ⁇ receptor by modifying one or more amino acids.
- ADCC antibody dependent cellular cytotoxicity
- This approach is described in, e.g., the PCT Publication WO 00/42072 by Presta.
- the binding sites on human IgG1 for Fc ⁇ RI, Fc ⁇ RII, Fc ⁇ RIII and FcRn have been mapped and variants with improved binding have been described (see Shields et al., J. Biol. Chem. 276: 6591-6604, 2001) .
- the glycosylation of an antibody is modified.
- an aglycosylated antibody can be made (i.e., the antibody lacks or has reduced glycosylation) .
- Glycosylation can be altered to, for example, increase the affinity of the antibody for “antigen. ”
- Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence.
- one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site.
- Such aglycosylation can increase the affinity of the antibody for antigen.
- Such an approach is described in, e.g., U.S. Pat. Nos. 5,714,350 and 6,350,861 by Co et al.
- an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures.
- altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies.
- carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies to thereby produce an antibody with altered glycosylation. For example, EP 1,176,195 by Hang et al.
- PCT Publication WO 99/54342 by Umana et al. describes cell lines engineered to express glycoprotein-modifying glycosyl transferases (e.g., beta (1, 4) -N acetylglucosaminyltransferase III (GnTIII) ) such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures which results in increased ADCC activity of the antibodies (see also Umana et al., Nat. Biotech. 17: 176-180, 1999) .
- glycoprotein-modifying glycosyl transferases e.g., beta (1, 4) -N acetylglucosaminyltransferase III (GnTIII)
- human antibody subclass IgG4 was shown in many previous reports to have only modest ADCC and almost no CDC effector function (Moore G L, et al. 2010 MAbs, 2: 181-189) .
- natural IgG4 was found less stable in stress conditions such as in acidic buffer or under increasing temperature (Angal, S. 1993 Mol Immunol, 30: 105-108; Dall'A cqua, W. et al, 1998 Biochemistry, 37: 9266-9273; Aalberse et al. 2002 Immunol, 105: 9-19) .
- Reduced ADCC can be achieved by operably linking the antibody to IgG4 engineered with combinations of alterations to have reduced or null Fc ⁇ R binding or C1q binding activities, thereby reducing or eliminating ADCC and CDC effector functions.
- IgG4 Considering physicochemical properties of antibody as a biological drug, one of the less desirable, intrinsic properties of IgG4 is dynamic separation of its two heavy chains in solution to form half antibody, which lead to bi-specific antibodies generated in vivo via a process called “Fab arm exchange” (Van der Neut Kolfschoten M, et al. 2007 Science, 317: 1554-157) .
- the mutation of serine to proline at position 228 appeared inhibitory to the IgG4 heavy chain separation (Angal, S.
- Ociperlimab and Tislelizumab antibodies and antigen-binding fragments thereof can be produced by any means known in the art, including but not limited to, recombinant expression, chemical synthesis, and enzymatic digestion of antibody tetramers, whereas full-length monoclonal antibodies can be obtained by, e.g., hybridoma or recombinant production.
- Recombinant expression can be from any appropriate host cells known in the art, for example, mammalian host cells, bacterial host cells, yeast host cells, insect host cells, etc.
- the disclosure further provides polynucleotides encoding the antibodies described herein, e.g., polynucleotides encoding heavy or light chain variable regions or segments comprising the complementarity determining regions as described herein.
- the polynucleotide encoding the heavy chain variable regions has at least 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%nucleic acid sequence identity with a polynucleotide that encodes for the polypeptides of Table 1 or Table 2.
- the polynucleotide encoding the light chain variable regions has at least 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%nucleic acid sequence identity with a polynucleotide that encodes for the polypeptides of Table 1 or Table 2.
- expression vectors and host cells for producing Ociperlimab and/or Tislelizumab antibodies.
- the choice of expression vector depends on the intended host cells in which the vector is to be expressed.
- the expression vectors contain a promoter and other regulatory sequences (e.g., enhancers) that are operably linked to the polynucleotides encoding an Ociperlimab and/or Tislelizumab antibody chain or antigen-binding fragment.
- an inducible promoter is employed to prevent expression of inserted sequences except under the control of inducing conditions.
- Inducible promoters include, e.g., arabinose, lacZ, metallothionein promoter or a heat shock promoter.
- Cultures of transformed organisms can be expanded under non-inducing conditions without biasing the population for coding sequences whose expression products are better tolerated by the host cells.
- other regulatory elements can also be required or desired for efficient expression of an Ociperlimab and/or Tislelizumab antibody or antigen-binding fragment. These elements typically include an ATG initiation codon and adjacent ribosome binding site or other sequences.
- the efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell system in use (see, e.g., Scharf et al., Results Probl. Cell Differ. 20: 125, 1994; and Bittner et al., Meth. Enzymol., 153: 516, 1987) .
- the SV40 enhancer or CMV enhancer can be used to increase expression in mammalian host cells.
- the host cells for harboring and expressing the Ociperlimab and/or Tislelizumab antibody chains can be either prokaryotic or eukaryotic.
- E. coli is one prokaryotic host useful for cloning and expressing the polynucleotides of the present disclosure.
- Other microbial hosts suitable for use include bacilli, such as Bacillus subtilis, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species.
- bacilli such as Bacillus subtilis
- enterobacteriaceae such as Salmonella, Serratia, and various Pseudomonas species.
- expression vectors which typically contain expression control sequences compatible with the host cell (e.g., an origin of replication) .
- any number of a variety of well-known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda.
- the promoters typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation.
- Other microbes, such as yeast can also be employed to express Ociperlimab and/or Tislelizumab polypeptides. Insect cells in combination with baculovirus vectors can also be used.
- mammalian host cells are used to express and produce the Ociperlimab and/or Tislelizumab polypeptides of the present disclosure.
- they can be either a hybridoma cell line expressing endogenous immunoglobulin genes or a mammalian cell line harboring an exogenous expression vector.
- These include any normal mortal or normal or abnormal immortal animal or human cell.
- suitable host cell lines capable of secreting intact immunoglobulins have been developed, including the CHO cell lines, various COS cell lines, HEK 293 cells, myeloma cell lines, transformed B-cells and hybridomas.
- Expression vectors for mammalian host cells can include expression control sequences, such as an origin of replication, a promoter, and an enhancer (see, e.g., Queen et al., Immunol. Rev. 89: 49-68, 1986) , and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences.
- expression control sequences such as an origin of replication, a promoter, and an enhancer (see, e.g., Queen et al., Immunol. Rev. 89: 49-68, 1986)
- necessary processing information sites such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences.
- These expression vectors usually contain promoters derived from mammalian genes or from mammalian viruses.
- Suitable promoters can be constitutive, cell type-specific, stage-specific, and/or modulatable or regulatable.
- Useful promoters include, but are not limited to, the metallothionein promoter, the constitutive adenovirus major late promoter, the dexamethasone-inducible MMTV promoter, the SV40 promoter, the MRP polIII promoter, the constitutive MPSV promoter, the tetracycline-inducible CMV promoter (such as the human immediate-early CMV promoter) , the constitutive CMV promoter, and promoter-enhancer combinations known in the art.
- the antibodies or antigen-binding fragments of the present disclosure are useful in a variety of applications including, but not limited to, methods for the detection of TIGIT.
- the antibodies or antigen-binding fragments are useful for detecting the presence of TIGIT in a biological sample.
- the term “detecting” as used herein includes quantitative or qualitative detection.
- a biological sample comprises a cell or tissue.
- such tissues include normal and/or cancerous tissues that express TIGIT at higher levels relative to other tissues.
- the present disclosure provides a method of detecting the presence of TIGIT in a biological sample.
- the method comprises contacting the biological sample with an anti-TIGIT antibody under conditions permissive for binding of the antibody to the antigen and detecting whether a complex is formed between the antibody and the antigen.
- the biological sample can include, without limitation, urine or blood samples.
- the method comprises contacting a test cell with an anti-TIGIT antibody; determining the level of expression (either quantitatively or qualitatively) of TIGIT in the test cell by detecting binding of the anti-TIGIT antibody to the TIGIT polypeptide; and comparing the level of expression in the test cell with the level of TIGIT expression in a control cell (e.g., a normal cell of the same tissue origin as the test cell or a non-TIGIT expressing cell) , wherein a higher level of TIGIT expression in the test cell as compared to the control cell indicates the presence of a disorder associated with expression of TIGIT.
- a control cell e.g., a normal cell of the same tissue origin as the test cell or a non-TIGIT expressing cell
- the antibodies or antigen-binding fragments of the present disclosure are useful in a variety of applications including, but not limited to, methods for the treatment of an TIGIT-associated disorder or disease.
- the TIGIT-associated disorder or disease is lymphoma and in certain aspects is DLBCL or refractory or relapsed DLBCL.
- the present disclosure provides a method of treating cancer.
- the method comprises administering to a patient in need an effective amount of an anti-TIGIT antibody or antigen-binding fragment.
- the cancer can include, without limitation, lymphoma, leukemia, DLBCL and refractory or relapsed DLBCL.
- An antibody or antigen-binding fragment of the invention can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
- Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g., by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
- Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
- Antibodies or antigen-binding fragments of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
- the antibody need not be but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99%of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
- an antibody or antigen- binding fragment of the invention will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
- the antibody is suitably administered to the patient at one time or over a series of treatments.
- about 1 ⁇ g/kg to 100 mg/kg of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
- One typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above.
- the treatment would generally be sustained until a desired suppression of disease symptoms occurs.
- Such doses can be administered intermittently, e.g., every week or every three weeks (e.g., such that the patient receives from about two to about twenty, or e.g., about six doses of the antibody) .
- An initial higher loading dose, followed by one or more lower doses can be administered.
- other dosage regimens can be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
- Ociperlimab antibodies can be used in combination with other therapeutic agents, for example anti-PD1 antibodies.
- Anti-PD1 antibodies can include, without limitation, Tislelizumab as described above.
- Pembrolizumab (formerly MK-3475) , as disclosed by Merck, is a humanized lgG4-K immunoglobulin with a molecular weight of about 149 kDa, which targets the PD1 receptor and inhibits binding of the PD1 receptor ligands PD-L1 and PD-L2.
- Pembrolizumab has been approved for the indications of metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) and is under clinical investigation for the treatment of head and neck squamous cell carcinoma (HNSCC) , and refractory Hodgkin's lymphoma (cHL) .
- NSCLC metastatic non-small cell lung cancer
- HNSCC head and neck squamous cell carcinoma
- cHL refractory Hodgkin's lymphoma
- Nivolumab (as disclosed by Bristol-Meyers Squibb is a fully human lgG4-K monoclonal antibody.
- Nivolumab (clone 5C4) is disclosed in US Patent No. US 8,008, 449 and WO 2006/121 168.
- Nivolumab is approved for the treatment of melanoma, lung cancer, kidney cancer, and Hodgkin's lymphoma.
- Ociperlimab antibodies can be used with anti-CD20 antibodies, which can include, without limitation, Rituximab (Rituxan) , Britumomab (Zevalin) , Tositumomab (Bexxar) and Obinutuzumab (Gazyva) .
- Anti-CD20 antibodies for example, Rituximab is directed against the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, these antibodies mediate B-cell lysis, with possible mechanisms of lysis including complement-dependent cytotoxicity (CDC) and ADCC.
- CDC complement-dependent cytotoxicity
- TLS Tumor lysis syndrome
- Another combination for the treatment of DLBCL includes the administration of Ociperlimab, Tislelizumab and/or Rituximab with the current treatments for DLBCL.
- Rituximab to a chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has significantly improved the clinical outcome (Coiffier et al., N Engl J Med. 2002; 346 (4) : 235-242) .
- compositions including pharmaceutical formulations, comprising an anti-TIGIT antibody or antigen-binding fragment, or polynucleotides comprising sequences encoding an anti-TIGIT antibody or antigen-binding fragment.
- compositions comprise one or more antibodies or antigen-binding fragments that bind to TIGIT, or one or more polynucleotides comprising sequences encoding one or more antibodies or antigen-binding fragments that bind to TIGIT.
- suitable carriers such as pharmaceutically acceptable excipients including buffers, which are well known in the art.
- compositions of an TIGIT antibody or antigen-binding fragment as described herein are prepared by mixing such antibody or antigen-binding fragment having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980) ) , in the form of lyophilized formulations or aqueous solutions.
- Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol) ; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine,
- sHASEGP soluble neutral-active hyaluronidase glycoproteins
- rHuPH20 Baxter International, Inc.
- a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
- Exemplary lyophilized antibody formulations are described in US Patent No. 6,267,958.
- Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.
- sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
- the formulations to be used for in vivo administration are generally sterile. Sterility can be readily accomplished, e.g., by filtration through sterile filtration membranes.
- compositions e.g., pharmaceutically acceptable compositions, which include an anti-TIGIT antibody described herein, formulated together with at least one pharmaceutically acceptable excipient.
- pharmaceutically acceptable excipient includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- the excipient can be suitable for intravenous, intramuscular, subcutaneous, parenteral, rectal, spinal or epidermal administration (e.g., by injection or infusion) .
- compositions herein may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusion solutions) , dispersions or suspensions, liposomes, and suppositories.
- liquid solutions e.g., injectable and infusion solutions
- dispersions or suspensions e.g., liposomes, and suppositories.
- a suitable form depends on the intended mode of administration and therapeutic application. Typical suitable compositions are in the form of injectable or infusion solutions.
- One suitable mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular) .
- the antibody is administered by intravenous infusion or injection.
- the antibody is administered by intramuscular or subcutaneous injection.
- Example 1 Ociperlimab and Tislelizumab in the treatment of DLBCL
- TIGIT and PD1 function as immune checkpoint receptors in the overlapping regulation of immune tolerance.
- Blockade of the TIGIT receptor alone or in combination with PD1/PD-L1 blockade has been shown both in vitro and in vivo to rescue functionally “exhausted” T-cells (Chauvin et al., J Clin Invest. 2015; 125: 2046-58) .
- TIGIT blockade in combination with anti-PD1/PD-L1 antibodies demonstrated significantly better antitumor efficacy than either monotherapy (Dixon et al., J Immunol. 2018; 200: 3000-7) .
- Clinically, treatment with Ociperlimab in combination with Tislelizumab has the potential to be more effective than Tislelizumab alone in DLBCL without prior checkpoint inhibitor therapy.
- the combination of tiragolumab plus atezolizumab reported an overall response rate of 31%and a progression free survival of 5.42 months versus placebo plus atezolizumab with an overall response rate of 16%and a progression free survival of 3.58 months in first-line Stage IV NSCLC patients with PD-L1 Tumor Proportion Score ⁇ 1% (Rodriguez-Abreu et al., J Clin Oncol. 2020; 38 (suppl 15): 9503) .
- the vibostolimab plus pembrolizumab combination reported an unconfirmed and confirmed ORR of 29%and 24%, respectively, in patients with NSCLC who were untreated or had been treated with at least 1 line of platinum-containing chemotherapy and had not previously received anti-PD1/PD-L1 therapy (Niu et al., Annals of Oncology 2020; 31: S891-2) .
- Cohort 1 -Cohort 1 DLBCL or R/R DLBCL patients with positive PD-L1 on the surface of tumor cells (with any expression level) will receive Ociperlimab in combination with Tislelizumab. Approximately 43 to 50 patients will be recruited for Cohort 1. Patients will receive a treatment cycle of 21 days. The combination of Ociperlimab with Tislelizumab will be administrated intravenously on Day 1 of each 21-day cycle continuously. Ociperlimab 900 mg in combination with Tislelizumab 200 mg will be administered on Day 1 of each 3-week cycle.
- Rituximab will be administered in combination with Ociperlimab, in either DLBCL or refractory/relapsed (R/R) DLBCL patients.
- Ociperlimab will synergize with Rituximab by enhancing T cell/NK-cell activation and Treg depletion/inhibition to promote both immediate tumor killing and long term memory immune response.
- the study will determine the preliminary antitumor activity of Ociperlimab in combination with Tislelizumab or Rituximab in patients with DLBCL or R/R DLBCL ( Figure 1) .
- eligible patients will be allocated to 2 cohorts based on PD-L1 expression level on the surface of tumor cells, which can be tested at local laboratory by immunohistochemistry IHC.
- Those patients that are PD-L1 negative will be assigned to Cohort 2-Cohort 2: DLBCL or R/R DLBCL patients with negative PD-L1 on the surface of tumor cells will receive Ociperlimab in combination with Rituximab.
- Ociperlimab Approximately 23 to 30 patients in Cohort 2 will be enrolled in the entire study. Every treatment cycle contains 21 days. The combination of Ociperlimab with Rituximab in Cohort 2 will be administrated intravenously on Day 1 of each 21-day cycle continuously. Ociperlimab will be tested at the dose level of 900mg initially. If Ociperlimab 900mg exceeds the MTD, Ociperlimab 600 mg will be tested. Other dose levels of Ociperlimab (e.g., lower than 600 mg) may be explored to confirm the optimal dose level of Ociperlimab in combination with Rituximab. The dose of Rituximab will be administered at 375 mg/m 2 .
- Example 3 Ociperlimab, Tislelizumab and Rituximab in the treatment of DLBCL
- TIGIT blockade by Ociperlimab has the potential to promote NK cell activation against poliovirus receptor+ (PVR+) tumor cells and to synergize the therapeutic monoclonal antibodies (such as Rituximab) mediated ADCC activity.
- PVR+ poliovirus receptor+
Abstract
Provided are methods of treating diffuse large B-cell lymphoma (DLBCL) or increasing, enhancing, or stimulating an immune response with antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains) and antigen-binding fragments thereof in combination with an anti-PD1 antibody and/or an anti-CD20 antibody.
Description
The present application relates to antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains) in combination with anti-PD1 antibodies and/or anti-CD20 antibodies for the treatment of lymphoma such as diffuse large B cell lymphoma (DLCBL) .
TIGIT (T cell immunoglobulin and ITIM domain) is a type I transmembrane protein, a member of the CD28 family of proteins that plays an important role in inhibiting T-and NK cell-mediated functional activities in anti-tumor immunity (Boles KS, et al., 2009 Eur J Immunol, 39: 695-703; Stanietsky N, et al., 2009 PNAS 106: 17858-63; Yu X, et al. 2009 Nat. Immunol, 10: 48-57) .
The genes and cDNAs coding for TIGIT were cloned and characterized in mouse and human. Full length human TIGIT has a sequence of 244 amino acids (SEQ ID NO: 1) in length, in which the first 21 amino acids consist of a signal peptide. The amino acid sequence of the mature human TIGIT contains 223 amino acid (aa) residues (NCBI accession number: NM_173799) . The extracellular domain (ECD) of mature human TIGIT consists of 120 amino acid residues (SEQ ID NO: 2, corresponding to amino acids 22-141 of SEQ ID NO: 1) with a V-type Ig-like domain (corresponding to amino acids 39-127 of SEQ ID NO: 1) , followed by a 21 aa transmembrane sequence, and an 82 aa cytoplasmic domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) (Yu X, et al. 2009 Nat. Immunol, 10: 48-57; Stengel KF, et al. 2012 PNAS 109: 5399-04) . Within the ECD, human TIGIT shares only 59%and 87%aa sequence identity with mouse and cynomolgus monkey, respectively.
Monoclonal antibodies that target either PD1 or PD-L1, can block this interaction and boost the immune response against cancer cells. These antibodies have been shown to be helpful in treating several types of cancer, including melanoma of the skin, non-small cell lung cancer (NSCLC) , kidney cancer, bladder cancer, head and neck cancers, and Hodgkin lymphoma. Cancer cells in most non-responders to single-agent checkpoint inhibitors escape through innate mechanisms that allow the cancer cells to grow and survive. As a result, disease progresses at a rate consistent with the natural history. However, unlike intrinsic resistance, late relapses are now emerging in patients with prior clinical benefit after longer follow-up of clinical trials, suggesting the emergence of acquired resistance (Jenkins et al., Br. J. Cancer 118, 9-16 2018) .
Anti-CD20 antibodies, for example, rituximab can be responsible for rapidly killing tumor targets via FcγR mediated ADCC or antibody dependent cellular phagocytosis (ADCP) , a short-term process mediated by natural killer cells and myeloid effector cells from innate immune system (Taylor and Lindorfer, Curr Opin Immunol. 2008; 20 (4) : 444-449; Minard-Colin et al., Blood. 2008; 112 (4) : 1205-1213) . Studies also reveal that the therapeutic function and long-term immune memory of anti-CD20 antibodies require active crosstalk with adaptive immunity. Evidence in lymphoma patients suggests that rituximab can induce a strong antitumor vaccinal effect by priming antitumor T cell responses, resulting in durable response (Cartron et al., Blood. 2004; 104 (9) : 2635-2642) . Using a murine lymphoma model to express human CD20, CD4+ and CD8+ T cells are demonstrated to be required for anti CD20 mAb
mediated long term memory immune response (Abes et al., Blood. 2010; 116 (6) : 926-934) , and the mechanism of anti-CD20 antibodies was shown to engage the macrophage for immediate ADCC and dendritic cells for long term antitumor cellular immune response (DiLillo et al., Cell. 2015; 161 (5) : 1035-1045) .
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease with a variable clinical outcome (Susanibar-Adaniya et al., Am J Hematol. 2021; 96 (5) : 617-629. ) and is the most common subtype of aggressive non-Hodgkin lymphomas (NHL) in the Western Countries, accounting for around 31%of NHL cases in adults. There were 544, 352 new cases of NHL and 259, 793 deaths resulting from this disease worldwide in 2020 (Sung et al., CA Cancer J Clin. 2021; 71 (3) : 209-249) . The incidence rate for DLBCL is approximately 6.9 cases per 100,000 person-years (Teras et al., CA Cancer J Clin. 2016 Nov 12; 66 (6) : 443-459) . Based on the study report of National Central Cancer Registry of China, an estimated of 88, 200 new lymphoma cases and 52, 100 lymphoma deaths occurred in China in 2015, ranked in the 12th and 11th place among all cancer cases, respectively (Chen et al., CA Cancer J Clin. 2016; 66 (2) : 115-132) . Two locally retrospective studies for NHL distributions in China showed that DLBCL made up about 29.1%and 40.9%of NHL, respectively (Liu et al., Asian Pac J Cancer Prev. 2011; 12 (11) : 3055-3061; Gross et al., China. Int J Hematol. 2008; 88 (2) : 165-173) . According to the current Surveillance Epidemiology and End Results (SEER) data, the median age at diagnosis is 66 years (SEER 2020) . Therefore, the combination of anti-TIGIT antibodies in combination with anti-PD1 antibodies can rescue immune cells from tolerance, inducing efficient immune responses in the treatment of cancer or chronic viral infections.
The present disclosure is directed methods of diffuse large B-cell lymphoma (DLBCL) treatment, administering anti-TIGIT antibodies in combination with anti-PD1 antibodies and/or anti-CD20 antibodies.
A method of diffuse large B-cell lymphoma (DLBCL) treatment, the method comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-PD1 antibody or antigen binding fragment thereof.
The method, wherein the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
The method, wherein the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
The method, wherein the anti-PD1 antibody comprises an antibody or an antigen binding fragment thereof which specifically binds human PD1, and comprises:
a heavy chain variable region that comprises: a HCDR1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14; and a light chain variable region that comprises LCDR1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17.
The method, wherein the anti-PD1 antibody or antigen binding fragment thereof which specifically binds human PD1 and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 18 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 19.
The method wherein the anti-PD1 antibody comprises an IgG4 constant domain comprising SEQ ID NO: 20.
The method wherein the anti-TIGIT antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab') 2 fragments.
The method wherein the anti-PD1 antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab') 2 fragments.
A method of diffuse large B-cell lymphoma (DLBCL) treatment, the method comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-CD20 antibody or antigen binding fragment thereof.
The method wherein the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
The method wherein the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
The method wherein the anti-CD20 antibody is Rituximab (Rituxan) , Britumomab (Zevalin) , Tositumomab (Bexxar) or Obinutuzumab (Gazyva) .
The method wherein the anti-CD20 antibody is Rituximab (Rituxan) .
The method wherein the DLBCL is relapsed or refractory DLBCL.
The method further comprising the administration of chemotherapy.
The method wherein the chemotherapy is cyclophosphamide, doxorubicin, vincristine, and prednisone.
The method wherein the anti-PD1 antibody is dosed at 200mg every three weeks.
The method wherein the anti-TIGIT antibody is dosed at a range of 50mg-900mg.
The method wherein the anti-TIGIT antibody is dosed at 50 mg every three weeks.
The method wherein the anti-TIGIT antibody is dosed at 150 mg every three weeks.
The method wherein the anti-TIGIT antibody is dosed at 450 mg every three weeks.
The method wherein the anti-TIGIT antibody is dosed at 900 mg every three weeks.
The method wherein Rituximab is administered at 375 mg/m2.
A method of diffuse large B-cell lymphoma (DLBCL) treatment, the method comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-CD20 antibody or antigen binding fragment thereof and an effective amount of an anti-PD1 antibody.
The method wherein the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
The method wherein the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
The method wherein the anti-PD1 antibody comprises an antibody or an antigen binding fragment thereof which specifically binds human PD1, and comprises: a heavy chain variable region that comprises: a HCDR1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14; and a light chain variable region that comprises LCDR1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17.
The method wherein the anti-PD1 antibody or antigen binding fragment thereof which specifically binds human PD1 and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 18 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 19.
The method further comprising the administration of chemotherapy.
The method wherein the chemotherapy is cyclophosphamide, doxorubicin, vincristine, and prednisone.
Figure 1 is a graphical representation of the therapeutics, their dosages and cohorts
Definitions
Conservative amino acid substitutions of amino acids are commonly known in the art and exemplarily shown in the table below. Generally, a conservative amino acid substitution means that an amino acid residue is replaced by another amino acid residue having a similar side chain.
Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.
As used herein, including the appended claims, the singular forms of words such as “a, ” “an, ” and “the” include their corresponding plural references unless the context clearly dictates otherwise.
The term “or” is used to mean, and is used interchangeably with, the term “and/or” unless the
context clearly dictates otherwise.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise" , and variations such as "comprises" and "comprising" , will be understood to imply the inclusion of a stated amino acid sequence, DNA sequence, step or group thereof, but not the exclusion of any other amino acid sequence, DNA sequence, step. When used herein the term "comprising" can be substituted with the term "containing" , “including” or sometimes "having. "
The term “TIGIT” includes various mammalian isoforms, e.g., human TIGIT, orthologs of human TIGIT, and analogs comprising at least one epitope within TIGIT. The amino acid sequence of TIGIT, e.g., human TIGIT, and the nucleotide sequence encoding the same, is known in the art (see Genbank AAI01289) .
“PD1” or “Programmed cell death protein 1” is a receptor that delivers inhibitory signals upon binding to ligands CD274/PD-L1 and CD273/PD-L2. The amino acid sequence of human PD1 is known in the art and can be found at accession number NP_005009 (Genbank) .
The term “CD-20” or “B-lymphocyte surface antigen B1” is a B-lymphocyte-specific membrane protein that aids in the regulation of cellular calcium influx. The amino acid of CD20 is set forth in Genbank accession number NP_068769.
The terms “administration, ” “administering, ” “treating” and “treatment” as used herein, when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, mean contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid. Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell. The term “administration” or “treatment” also includes in vitro and ex vivo treatments, e.g., of a cell, by a reagent, diagnostic, binding compound, or by another cell. The term “subject” herein refers to any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, rabbit) and most preferably a human.
The term “antibody” herein is used in the broadest sense and specifically covers antibodies (including full length monoclonal antibodies) and antibody fragments so long as they recognize antigen, e.g., TIGIT. An antibody is usually monospecific, but may also be described as idiospecific, heterospecific, or polyspecific. Antibody molecules bind by means of specific binding sites to specific antigenic determinants or epitopes on antigens.
The term “monoclonal antibody” or “mAb” or “Mab” herein means a population of substantially homogeneous antibodies, i.e., the antibody molecules comprised in the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts. In contrast, conventional (polyclonal) antibody preparations typically include a multitude of different antibodies having different amino acid sequences in their variable domains, particularly their complementarity determining regions (CDRs) , which are often specific for different epitopes. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. Monoclonal antibodies (mAbs) may be obtained by methods known to those skilled in the art. See, for example Kohler G et al., Nature 1975 256: 495-497; U.S. Pat. No. 4,376,110;
Ausubel FM et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY 1992; Harlow E et al., ANTIBODIES: A LABORATORY MANUAL, Cold spring Harbor Laboratory 1988; and Colligan JE et al., CURRENT PROTOCOLS IN IMMUNOLOGY 1993. The mAbs disclosed herein may be of any immunoglobulin class including IgG, IgM, IgD, IgE, IgA, and any subclass thereof. A hybridoma producing a mAb may be cultivated in vitro or in vivo. High titers of mAbs can be obtained by in vivo production where cells from the individual hybridomas are injected intraperitoneally into mice, such as pristine-primed Balb/c mice to produce ascites fluid containing high concentrations of the desired mAbs. MAbs of isotype IgM or IgG may be purified from such ascites fluids, or from culture supernatants, using column chromatography methods well known to those of skill in the art.
In general, the basic antibody structural unit comprises a tetramer. Each tetramer includes two identical pairs of polypeptide chains, each pair having one “light chain” (about 25 kDa) and one “heavy chain” (about 50-70 kDa) . The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of the heavy chain may define a constant region primarily responsible for effector function. Typically, human light chains are classified as kappa and lambda light chains. Furthermore, human heavy chains are typically classified as α, δ, ε, γ, or μ, and define the antibody's isotypes as IgA, IgD, IgE, IgG, and IgM, respectively. Within light and heavy chains, the variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids.
The variable regions of each light/heavy chain (VL/VH) pair form the antibody binding site. Thus, in general, an intact antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are, in general, the same.
Typically, the variable domains of both the heavy and light chains comprise three hypervariable regions, also called “complementarity determining regions (CDRs) ” , which are located between relatively conserved framework regions (FR) . The CDRs are usually aligned by the framework regions, enabling binding to a specific epitope. In general, from N-terminal to C-terminal, both light and heavy chain variable domains sequentially comprise FR-1 (or FR1) , CDR-1 (or CDR1) , FR-2 (FR2) , CDR-2 (CDR2) , FR-3 (or FR3) , CDR-3 (CDR3) , and FR-4 (or FR4) . The assignment of amino acids to each domain is, generally, in accordance with the definitions of Sequences of Proteins of Immunological Interest, Kabat, et al., National Institutes of Health, Bethesda, Md.; 5th ed.; NIH Publ. No. 91-3242 (1991) ; Kabat (1978) Adv. Prot. Chem. 32: 1-75; Kabat, et al., (1977) J. Biol. Chem. 252: 6609-6616; Chothia, et al, (1987) J Mol. Biol. 196: 901-917 or Chothia, et al., (1989) Nature 342: 878-883.
The term “hypervariable region” means the amino acid residues of an antibody that are responsible for antigen-binding. The hypervariable region comprises amino acid residues from a “CDR” (i.e., VL-CDR1, VL-CDR2 and VL-CDR3 in the light chain variable domain and VH-CDR1, VH-CDR2 and VH-CDR3 in the heavy chain variable domain) . See, Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (defining the CDR regions of an antibody by sequence) ; see also Chothia and Lesk (1987) J. Mol. Biol. 196: 901-917 (defining the CDR regions of an antibody by structure) . The term “framework” or “FR” residues mean those variable domain residues other than the hypervariable region residues defined herein
as CDR residues.
Unless otherwise indicated, “antibody fragment” or “antigen-binding fragment” means antigen binding fragments of antibodies, i.e., antibody fragments that retain the ability to bind specifically to the antigen bound by the full-length antibody, e.g., fragments that retain one or more CDR regions. Examples of antigen binding fragments include, but not limited to, Fab, Fab', F (ab') 2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, e.g., single chain Fv (ScFv) ; nanobodies and multispecific antibodies formed from antibody fragments.
An antibody that binds to a specified target protein with specificity is also described as specifically binding to a specified target protein. This means the antibody exhibits preferential binding to that target as compared to other proteins, but this specificity does not require absolute binding specificity. An antibody is considered “specific” for its intended target if its binding is determinative of the presence of the target protein in a sample, e.g., without producing undesired results such as false positives. Antibodies or binding fragments thereof, useful in the present invention will bind to the target protein with an affinity that is at least two-fold greater, preferably at least 10-times greater, more preferably at least 20-times greater, and most preferably at least 100-times greater than the affinity with non-target proteins. An antibody herein is said to bind specifically to a polypeptide comprising a given amino acid sequence, e.g., the amino acid sequence of a mature human TIGIT molecule, if it binds to polypeptides comprising that sequence but does not bind to proteins lacking that sequence.
The expressions “pH-dependent binding” , “pH-dependent target binding” and “pH-dependent antigen binding” are interchangeable in the present disclosure, indicating that the antibody of the present application binds to its target/antigen, namely human TIGIT, in a pH-dependent manner. Specifically, the antibody of the present application shows a higher binding affinity and/or binding signal to its antigen at a mild acidic pH, e.g., pH 6.0, which is usually found in tumor microenvironment, as compared to the binding affinity and/or binding signal at physiologic pH, e.g., pH 7.4. The methods for determining the binding affinity and/or the intensity of binding signal of the antibody of the present application are well known in the art and include but not limited to surface plasmon resonance (Biacore) or similar technology. More specifically, the antibody of the present application has a KD ratio at pH 7.4/pH 6.0 of greater than 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more, as measured by surface plasmon resonance (Biacore) or similar technology. Alternatively, or additionally, the antibody of the present application has a Rmax (RU) value at pH 6.0 which is at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold higher than the Rmax at pH 7.4 as measured by surface plasmon resonance (Biacore) or similar technology. The binding affinity of the antibody can be measured at 25℃ or 37℃. Tumor microenvironment has been found to show a relatively more acidic pH than physiological condition or normal tissues. Therefore, the antibody of the present application having above-mentioned pH-dependent binding is advantageous as an anti-TIGIT therapeutic agent for targeting TIGIT-positive lymphocytes in the tumor microenvironment with selectivity and having lower toxicity associated with periphery activation of lymphocytes.
The term “human antibody” herein means an antibody that comprises human immunoglobulin protein sequences only. A human antibody may contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell. Similarly, “mouse antibody” or “rat
antibody” means an antibody that comprises only mouse or rat immunoglobulin protein sequences, respectively.
The term “humanized antibody” means forms of antibodies that contain sequences from non-human (e.g., murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc) , typically that of a human immunoglobulin. The prefix “hum, ” “hu, ” “Hu” or “h” is added to antibody clone designations when necessary to distinguish humanized antibodies from parental rodent antibodies. The humanized forms of rodent antibodies will generally comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions may be included to increase affinity, increase stability of the humanized antibody, or for other reasons.
The antibody of the present application has potential therapeutic uses in treating cancer. The term “cancer” or “tumor” herein means or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, leukemia, lymphoma, diffuse large B-cell lymphoma (DLBCL) and relapsed or refractory DLBCL.
Further, the antibody of the present application has potential therapeutic uses in controlling viral infections and other human diseases that are mechanistically involved in immune tolerance or ″exhaustion. ” In the context of the present application, the term “exhaustion” refers to a process which leads to a depleted ability of immune cells to respond during to a cancer or a chronic viral infection.
The term “therapeutically effective amount” as herein used, refers to the amount of an antibody that, when administered to a subject for treating a disease or a disorder, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or symptom. The “therapeutically effective amount” can vary with the antibody, the disease, disorder, and/or symptoms of the disease or disorder, severity of the disease, disorder, and/or symptoms of the disease or disorder, the age of the subject to be treated, and/or the weight of the subject to be treated. An appropriate amount in any given instance can be apparent to those skilled in the art or can be determined by routine experiments. In the case of combination therapy, the “therapeutically effective amount” refers to the total amount of the active agents comprised in the combination for the effective treatment of a disease, a disorder or a condition.
The “subject” as used herein is a mammal, e.g., a rodent or a primate, preferably a higher primate, e.g., a human (e.g., a patient having, or at risk of having, a disorder described herein) .
Anti-TIGIT antibodies
The present disclosure provides for antibodies, antigen-binding fragments, that specifically bind human TIGIT. Furthermore, the present disclosure provides antibodies that have desirable pharmacokinetic characteristics and other desirable attributes, and thus can be used for the treatment of lymphoma, for example, DLBCL. The present disclosure further provides pharmaceutical compositions comprising the antibodies and methods of making and using such pharmaceutical compositions for the
prevention and treatment of DLBCL and associated disorders.
The present disclosure provides for antibodies or antigen-binding fragments thereof that specifically bind to TIGIT. Anti-TIGIT antibodies are also provided herein and comprise, for example, a heavy chain variable region (VH) comprising the complementarity determining regions (CDRs) : HCDR1 as set forth in SEQ ID NO: 1 , HCDR2 as set forth in SEQ ID NO: 2, and HCDR3 as set forth in SEQ ID NO: 3; and a light chain variable region (VL) comprising: LCDR1 as set forth in SEQ ID NO: 4, LCDR2 as set forth in SEQ ID NO: 5, and LCDR3 as set forth in SEQ ID NO: 6. Antibodies or antigen-binding fragments of the present disclosure include, but are not limited to, the antibodies or antigen-binding fragments thereof, as described in Table 1 below, which is designated “BGB-A1217” or “Ociperlimab. ”
Table 1
Anti-PD1 antibodies
PD1 antibodies are also provided herein and comprise, for example, a heavy chain variable region (VH) comprising the complementarity determining regions (CDRs) : HCDR1 as set forth in SEQ ID NO: 12 , HCDR2 as set forth in SEQ ID NO: 13, and HCDR3 as set forth in SEQ ID NO: 14; and a light chain variable region (VL) comprising: LCDR1 as set forth in SEQ ID NO: 15, LCDR2 as set forth in SEQ ID NO: 16, and LCDR3 as set forth in SEQ ID NO: 17. This antibody is designated herein as “BGB-A317” or “Tislelizumab” and the sequences of this antibody are set forth in Table 2.
Table 2
Further Alteration of the Framework of Fc Region
In yet other aspects, the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector functions of the antibody. For example, one or more amino acids can be replaced with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains the antigen-binding ability of the parent antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in, e.g., U.S. Pat. Nos. 5,624,821 and 5,648,260, both by Winter et al.
In another aspect, one or more amino acid residues can be replaced with one or more different amino acid residues such that the antibody has altered C1q binding and/or reduced or abolished complement dependent cytotoxicity (CDC) . This approach is described in, e.g., U.S. Pat. No. 6,194,551 by Idusogie et al.
In yet another aspect, one or more amino acid residues are altered to thereby alter the ability of the antibody to fix complement. This approach is described in, e.g., the PCT Publication WO 94/29351 by Bodmer et al. In a specific aspect, one or more amino acids of an antibody or antigen-binding fragment thereof of the present disclosure are replaced by one or more allotypic amino acid residues, for the IgG1 subclass and the kappa isotype. Allotypic amino acid residues also include, but are not limited to, the constant region of the heavy chain of the IgG1, IgG2, and IgG3 subclasses as well as the constant region of the light chain of the kappa isotype as described by Jefferis et al., MAbs. 1: 332-338 (2009) .
In another aspect, the Fc region is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or to increase the affinity of the antibody for an Fcγreceptor by modifying one or more amino acids. This approach is described in, e.g., the PCT Publication WO 00/42072 by Presta. Moreover, the binding sites on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn have been mapped and variants with improved binding have been described (see Shields et al., J. Biol. Chem. 276: 6591-6604, 2001) .
In still another aspect, the glycosylation of an antibody is modified. For example, an aglycosylated antibody can be made (i.e., the antibody lacks or has reduced glycosylation) . Glycosylation can be altered to, for example, increase the affinity of the antibody for “antigen. ” Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site. Such aglycosylation can increase the affinity of the antibody for antigen. Such an approach is described in, e.g., U.S. Pat. Nos. 5,714,350 and 6,350,861 by Co et al.
Additionally, or alternatively, an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures. Such altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies. Such carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies to thereby produce an antibody with altered glycosylation. For example, EP 1,176,195 by Hang et al. describes a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyl transferase, such that antibodies expressed in such a cell line exhibit hypofucosylation. PCT Publication WO 03/035835 by Presta describes a variant CHO cell line, Lecl3 cells, with reduced ability to attach fucose to Asn (297) -linked carbohydrates, also resulting in hypofucosylation of antibodies expressed in that host cell (see also Shields et al., (2002) J. Biol. Chem. 277: 26733-26740) . PCT Publication WO 99/54342 by Umana et al., describes cell lines engineered to express glycoprotein-modifying glycosyl transferases (e.g., beta (1, 4) -N acetylglucosaminyltransferase III (GnTIII) ) such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures which results in increased ADCC activity of the antibodies (see also Umana et al., Nat. Biotech. 17: 176-180, 1999) .
In another aspect, if a reduction of ADCC is desired, human antibody subclass IgG4 was shown in many previous reports to have only modest ADCC and almost no CDC effector function (Moore G L, et al. 2010 MAbs, 2: 181-189) . On the other hand, natural IgG4 was found less stable in stress conditions such as in acidic buffer or under increasing temperature (Angal, S. 1993 Mol Immunol, 30: 105-108; Dall'A cqua, W. et al, 1998 Biochemistry, 37: 9266-9273; Aalberse et al. 2002 Immunol, 105: 9-19) . Reduced ADCC can be achieved by operably linking the antibody to IgG4 engineered with combinations of alterations to have reduced or null FcγR binding or C1q binding activities, thereby reducing or eliminating ADCC and CDC effector functions. Considering physicochemical properties of antibody as a biological drug, one of the less desirable, intrinsic properties of IgG4 is dynamic separation of its two
heavy chains in solution to form half antibody, which lead to bi-specific antibodies generated in vivo via a process called “Fab arm exchange” (Van der Neut Kolfschoten M, et al. 2007 Science, 317: 1554-157) . The mutation of serine to proline at position 228 (EU numbering system) appeared inhibitory to the IgG4 heavy chain separation (Angal, S. 1993 Mol Immunol, 30: 105-108; Aalberse et al. 2002 Immunol, 105: 9-19) . Some of the amino acid residues in the hinge and γFc region were reported to have impact on antibody interaction with Fcγ receptors (Chappel S M, et al. 1991 Proc. Natl. Acad. Sci. USA, 88: 9036-9040; Mukherjee, J. et al., 1995 FASEB J, 9: 115-119; Armour, K.L. et al. 1999 Eur J Immunol, 29: 2613-2624; Clynes, R. A. et al, 2000 Nature Medicine, 6: 443-446; Arnold J.N., 2007 Annu Rev immunol, 25: 21-50) . Furthermore, some rarely occurring IgG4 isoforms in human population can also elicit different physicochemical properties (Brusco, A. et al. 1998 Eur J Immunogenet, 25: 349-55; Aalberse et al. 2002 Immunol, 105: 9-19) .
Antibody Production
Ociperlimab and Tislelizumab antibodies and antigen-binding fragments thereof can be produced by any means known in the art, including but not limited to, recombinant expression, chemical synthesis, and enzymatic digestion of antibody tetramers, whereas full-length monoclonal antibodies can be obtained by, e.g., hybridoma or recombinant production. Recombinant expression can be from any appropriate host cells known in the art, for example, mammalian host cells, bacterial host cells, yeast host cells, insect host cells, etc.
The disclosure further provides polynucleotides encoding the antibodies described herein, e.g., polynucleotides encoding heavy or light chain variable regions or segments comprising the complementarity determining regions as described herein. In some aspects, the polynucleotide encoding the heavy chain variable regions has at least 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%nucleic acid sequence identity with a polynucleotide that encodes for the polypeptides of Table 1 or Table 2. In some aspects, the polynucleotide encoding the light chain variable regions has at least 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%nucleic acid sequence identity with a polynucleotide that encodes for the polypeptides of Table 1 or Table 2.
Also provided in the present disclosure are expression vectors and host cells for producing Ociperlimab and/or Tislelizumab antibodies. The choice of expression vector depends on the intended host cells in which the vector is to be expressed. Typically, the expression vectors contain a promoter and other regulatory sequences (e.g., enhancers) that are operably linked to the polynucleotides encoding an Ociperlimab and/or Tislelizumab antibody chain or antigen-binding fragment. In some aspects, an inducible promoter is employed to prevent expression of inserted sequences except under the control of inducing conditions. Inducible promoters include, e.g., arabinose, lacZ, metallothionein promoter or a heat shock promoter. Cultures of transformed organisms can be expanded under non-inducing conditions without biasing the population for coding sequences whose expression products are better tolerated by the host cells. In addition to promoters, other regulatory elements can also be required or desired for efficient expression of an Ociperlimab and/or Tislelizumab antibody or antigen-binding fragment. These elements typically include an ATG initiation codon and adjacent ribosome binding site or other sequences. In addition, the efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell system in use (see, e.g., Scharf et al., Results Probl. Cell Differ. 20: 125, 1994; and Bittner et al.,
Meth. Enzymol., 153: 516, 1987) . For example, the SV40 enhancer or CMV enhancer can be used to increase expression in mammalian host cells.
The host cells for harboring and expressing the Ociperlimab and/or Tislelizumab antibody chains can be either prokaryotic or eukaryotic. E. coli is one prokaryotic host useful for cloning and expressing the polynucleotides of the present disclosure. Other microbial hosts suitable for use include bacilli, such as Bacillus subtilis, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species. In these prokaryotic hosts, one can also make expression vectors, which typically contain expression control sequences compatible with the host cell (e.g., an origin of replication) . In addition, any number of a variety of well-known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation. Other microbes, such as yeast, can also be employed to express Ociperlimab and/or Tislelizumab polypeptides. Insect cells in combination with baculovirus vectors can also be used.
In other aspects, mammalian host cells are used to express and produce the Ociperlimab and/or Tislelizumab polypeptides of the present disclosure. For example, they can be either a hybridoma cell line expressing endogenous immunoglobulin genes or a mammalian cell line harboring an exogenous expression vector. These include any normal mortal or normal or abnormal immortal animal or human cell. For example, a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed, including the CHO cell lines, various COS cell lines, HEK 293 cells, myeloma cell lines, transformed B-cells and hybridomas. The use of mammalian tissue cell culture to express polypeptides is discussed generally in, e.g., Winnacker, From Genes to Clones, VCH Publishers, NY, N.Y., 1987. Expression vectors for mammalian host cells can include expression control sequences, such as an origin of replication, a promoter, and an enhancer (see, e.g., Queen et al., Immunol. Rev. 89: 49-68, 1986) , and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. These expression vectors usually contain promoters derived from mammalian genes or from mammalian viruses. Suitable promoters can be constitutive, cell type-specific, stage-specific, and/or modulatable or regulatable. Useful promoters include, but are not limited to, the metallothionein promoter, the constitutive adenovirus major late promoter, the dexamethasone-inducible MMTV promoter, the SV40 promoter, the MRP polIII promoter, the constitutive MPSV promoter, the tetracycline-inducible CMV promoter (such as the human immediate-early CMV promoter) , the constitutive CMV promoter, and promoter-enhancer combinations known in the art.
Methods of Detection and Diagnosis
The antibodies or antigen-binding fragments of the present disclosure are useful in a variety of applications including, but not limited to, methods for the detection of TIGIT. In one aspect, the antibodies or antigen-binding fragments are useful for detecting the presence of TIGIT in a biological sample. The term “detecting” as used herein includes quantitative or qualitative detection. In certain aspects, a biological sample comprises a cell or tissue. In other aspects, such tissues include normal and/or cancerous tissues that express TIGIT at higher levels relative to other tissues.
In one aspect, the present disclosure provides a method of detecting the presence of TIGIT in a biological sample. In certain aspects, the method comprises contacting the biological sample with an anti-TIGIT antibody under conditions permissive for binding of the antibody to the antigen and detecting whether a complex is formed between the antibody and the antigen. The biological sample can include, without limitation, urine or blood samples.
Also included is a method of diagnosing a disorder associated with expression of TIGIT. In certain aspects, the method comprises contacting a test cell with an anti-TIGIT antibody; determining the level of expression (either quantitatively or qualitatively) of TIGIT in the test cell by detecting binding of the anti-TIGIT antibody to the TIGIT polypeptide; and comparing the level of expression in the test cell with the level of TIGIT expression in a control cell (e.g., a normal cell of the same tissue origin as the test cell or a non-TIGIT expressing cell) , wherein a higher level of TIGIT expression in the test cell as compared to the control cell indicates the presence of a disorder associated with expression of TIGIT.
Methods of Treatment
The antibodies or antigen-binding fragments of the present disclosure are useful in a variety of applications including, but not limited to, methods for the treatment of an TIGIT-associated disorder or disease. In one aspect, the TIGIT-associated disorder or disease is lymphoma and in certain aspects is DLBCL or refractory or relapsed DLBCL.
In one aspect, the present disclosure provides a method of treating cancer. In certain aspects, the method comprises administering to a patient in need an effective amount of an anti-TIGIT antibody or antigen-binding fragment. The cancer can include, without limitation, lymphoma, leukemia, DLBCL and refractory or relapsed DLBCL.
An antibody or antigen-binding fragment of the invention can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g., by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
Antibodies or antigen-binding fragments of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody need not be but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99%of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
For the prevention or treatment of disease, the appropriate dosage of an antibody or antigen-
binding fragment of the invention will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg/kg to 100 mg/kg of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. Such doses can be administered intermittently, e.g., every week or every three weeks (e.g., such that the patient receives from about two to about twenty, or e.g., about six doses of the antibody) . An initial higher loading dose, followed by one or more lower doses can be administered. However, other dosage regimens can be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
Combination Therapy
In one aspect, Ociperlimab antibodies can be used in combination with other therapeutic agents, for example anti-PD1 antibodies. Anti-PD1 antibodies can include, without limitation, Tislelizumab as described above. Pembrolizumab (formerly MK-3475) , as disclosed by Merck, is a humanized lgG4-K immunoglobulin with a molecular weight of about 149 kDa, which targets the PD1 receptor and inhibits binding of the PD1 receptor ligands PD-L1 and PD-L2. Pembrolizumab has been approved for the indications of metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) and is under clinical investigation for the treatment of head and neck squamous cell carcinoma (HNSCC) , and refractory Hodgkin's lymphoma (cHL) . Nivolumab (as disclosed by Bristol-Meyers Squibb is a fully human lgG4-K monoclonal antibody. Nivolumab (clone 5C4) is disclosed in US Patent No. US 8,008, 449 and WO 2006/121 168. Nivolumab is approved for the treatment of melanoma, lung cancer, kidney cancer, and Hodgkin's lymphoma.
In another aspect, Ociperlimab antibodies can be used with anti-CD20 antibodies, which can include, without limitation, Rituximab (Rituxan) , Britumomab (Zevalin) , Tositumomab (Bexxar) and Obinutuzumab (Gazyva) . Anti-CD20 antibodies, for example, Rituximab is directed against the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, these antibodies mediate B-cell lysis, with possible mechanisms of lysis including complement-dependent cytotoxicity (CDC) and ADCC. Most common adverse events associated with Rituximab (≥ 25%) in clinical trials for NHL were infusion reaction, fever, lymphopenia, chills, infection, and asthenia. Tumor lysis syndrome (TLS) can be associated with Rituximab treatment in patients with NHL, with a high number of circulating malignant cells (≥ 25,000/mm3) or high tumor burden conferring a greater risk of TLS. Rituximab is currently approved for treatment of CD20+ NHL, including CD20+ DLBCL.
Another combination for the treatment of DLBCL includes the administration of Ociperlimab, Tislelizumab and/or Rituximab with the current treatments for DLBCL. The addition of Rituximab to a chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has significantly improved the clinical outcome (Coiffier et al., N Engl J Med. 2002; 346 (4) : 235-242) .
Recently, the Phase III POLARIX study comparing polatuzumab vedotin in combination with chemotherapy regimen R-CHP versus the standard of care R-CHOP in treatment of first line DLBCL met its primary endpoint by demonstrating significantly improved and clinically meaningful progression free survival. However, 30%to 40%of patients with DLBCL eventually relapse and 10%of them are primary refractory, which remains as a consistent clinical problem (Flowers et al., CA Cancer J Clin. 2010; 60 (6) : 393-408) . Thus, the combination of Ociperlimab, Tislelizumab and/or Rituximab with the administration of chemotherapy can prove useful in the treatment of DLBCL and refractory or relapsed DLBCL.
Pharmaceutical compositions and formulations
Also provided are compositions, including pharmaceutical formulations, comprising an anti-TIGIT antibody or antigen-binding fragment, or polynucleotides comprising sequences encoding an anti-TIGIT antibody or antigen-binding fragment. In certain embodiments, compositions comprise one or more antibodies or antigen-binding fragments that bind to TIGIT, or one or more polynucleotides comprising sequences encoding one or more antibodies or antigen-binding fragments that bind to TIGIT. These compositions can further comprise suitable carriers, such as pharmaceutically acceptable excipients including buffers, which are well known in the art.
Pharmaceutical formulations of an TIGIT antibody or antigen-binding fragment as described herein are prepared by mixing such antibody or antigen-binding fragment having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980) ) , in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol) ; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes) ; and/or non-ionic surfactants such as polyethylene glycol (PEG) . Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP) , for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (Baxter International, Inc. ) . Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Nos. US 7,871,607 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
Exemplary lyophilized antibody formulations are described in US Patent No. 6,267,958. Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.
Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
The formulations to be used for in vivo administration are generally sterile. Sterility can be readily accomplished, e.g., by filtration through sterile filtration membranes.
Pharmaceutical Compositions and Kits
In some aspects, this disclosure provides compositions, e.g., pharmaceutically acceptable compositions, which include an anti-TIGIT antibody described herein, formulated together with at least one pharmaceutically acceptable excipient. As used herein, the term “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible. The excipient can be suitable for intravenous, intramuscular, subcutaneous, parenteral, rectal, spinal or epidermal administration (e.g., by injection or infusion) .
The compositions herein may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusion solutions) , dispersions or suspensions, liposomes, and suppositories. A suitable form depends on the intended mode of administration and therapeutic application. Typical suitable compositions are in the form of injectable or infusion solutions. One suitable mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular) . In some embodiments, the antibody is administered by intravenous infusion or injection. In certain embodiments, the antibody is administered by intramuscular or subcutaneous injection.
EXAMPLE
Example 1: Ociperlimab and Tislelizumab in the treatment of DLBCL
TIGIT and PD1 function as immune checkpoint receptors in the overlapping regulation of immune tolerance. Blockade of the TIGIT receptor alone or in combination with PD1/PD-L1 blockade has been shown both in vitro and in vivo to rescue functionally “exhausted” T-cells (Chauvin et al., J Clin Invest. 2015; 125: 2046-58) . In mouse models, TIGIT blockade in combination with anti-PD1/PD-L1 antibodies demonstrated significantly better antitumor efficacy than either monotherapy (Dixon et al., J Immunol. 2018; 200: 3000-7) . Clinically, treatment with Ociperlimab in combination with Tislelizumab has the potential to be more effective than Tislelizumab alone in DLBCL without prior checkpoint inhibitor therapy.
For example, the combination of tiragolumab plus atezolizumab reported an overall response rate of 31%and a progression free survival of 5.42 months versus placebo plus atezolizumab with an overall response rate of 16%and a progression free survival of 3.58 months in first-line Stage IV NSCLC patients with PD-L1 Tumor Proportion Score ≥ 1% (Rodriguez-Abreu et al., J Clin Oncol. 2020; 38 (suppl 15): 9503) . Similarly, the vibostolimab plus pembrolizumab combination reported an unconfirmed and confirmed ORR of 29%and 24%, respectively, in patients with NSCLC who were untreated or had been treated with at least 1 line of platinum-containing chemotherapy and had not previously received anti-PD1/PD-L1 therapy (Niu et al., Annals of Oncology 2020; 31: S891-2) .
Gene expression analysis has previously verified upregulation of TIGIT and PD-L1 in DLBCL compared with normal controls (Laurent et al., 2015; 4 (8) : e1026530) . Characterization of coinhibitory
receptor expression in intratumoral T cells from DLBCL revealed that both TIGIT and PD1 were expressed at higher frequency than all other receptors such asTIM-3 and LAG-3. The co-expression pattern of TIGIT and PD1 not only contributes to impaired T-cell effector function as tested by cytokine production, but also inhibits the antitumor activity of T cell through interaction with ligand-expressing tumor cells in DLBCL (CD155 and CD122 expression) . All these indicate the value of combinatorial blockade of TIGIT and PD1 in DLBCL and exploration for mechanisms of immune escape by characterizing the tumor microenvironment (Josefsson et al., Cancer Immunol Res. 2019; 7 (3) : 355-362) .
However, the limitation of single agent of anti-PD1 is also observed in patients with R/R DLBCL, with the overall response rate of approximately 10%. A trend of increasing overall response rate and complete response rate was observed in patients with high PD-L1 expression on the surface of tumor cells in a combination therapy of nivolumab and ibrutinib. Given the tolerable and manageable safety profile of Tislelizumab in DLBCL and the scientific rationale of synergistic antitumor effects between anti-TIGIT and anti-PD1 therapies, the combination of Ociperlimab and Tislelizumab can bring significant clinical benefit in R/R DLBCL in PD-L1 positive patients and supports further clinical development.
Safety and efficacy data of Tislelizumab in NHL (including DLBCL) are available from one ongoing combination therapy study. A Phase 1b, open label, multiple-dose, dose-escalation, and dose expansion study of Zanubrutinib in combination with Tislelizumab in patients with B-cell lymphoid malignancies (i.e., NHL) is currently on-going.
For patients that are PD-L1 positive, they will be relegated to Cohort 1 -Cohort 1: DLBCL or R/R DLBCL patients with positive PD-L1 on the surface of tumor cells (with any expression level) will receive Ociperlimab in combination with Tislelizumab. Approximately 43 to 50 patients will be recruited for Cohort 1. Patients will receive a treatment cycle of 21 days. The combination of Ociperlimab with Tislelizumab will be administrated intravenously on Day 1 of each 21-day cycle continuously. Ociperlimab 900 mg in combination with Tislelizumab 200 mg will be administered on Day 1 of each 3-week cycle.
Example 2: Ociperlimab and Rituximab in the treatment of DLBCL
To ensure the maximum clinical benefit for DLBCL patients that are PD-L1 negative, Rituximab will be administered in combination with Ociperlimab, in either DLBCL or refractory/relapsed (R/R) DLBCL patients. Ociperlimab will synergize with Rituximab by enhancing T cell/NK-cell activation and Treg depletion/inhibition to promote both immediate tumor killing and long term memory immune response.
The study will determine the preliminary antitumor activity of Ociperlimab in combination with Tislelizumab or Rituximab in patients with DLBCL or R/R DLBCL (Figure 1) . As described above, eligible patients will be allocated to 2 cohorts based on PD-L1 expression level on the surface of tumor cells, which can be tested at local laboratory by immunohistochemistry IHC. Those patients that are PD-L1 negative will be assigned to Cohort 2-Cohort 2: DLBCL or R/R DLBCL patients with negative PD-L1 on the surface of tumor cells will receive Ociperlimab in combination with Rituximab.
Approximately 23 to 30 patients in Cohort 2 will be enrolled in the entire study. Every treatment cycle contains 21 days. The combination of Ociperlimab with Rituximab in Cohort 2 will be
administrated intravenously on Day 1 of each 21-day cycle continuously. Ociperlimab will be tested at the dose level of 900mg initially. If Ociperlimab 900mg exceeds the MTD, Ociperlimab 600 mg will be tested. Other dose levels of Ociperlimab (e.g., lower than 600 mg) may be explored to confirm the optimal dose level of Ociperlimab in combination with Rituximab. The dose of Rituximab will be administered at 375 mg/m2.
Example 3: Ociperlimab, Tislelizumab and Rituximab in the treatment of DLBCL
For DLBCL or R/R DLBCL patients that are PD-L1 positive, the administration of Ociperlimab, Tislelizumab, Rituximab and chemotherapy will be explored. TIGIT blockade by Ociperlimab has the potential to promote NK cell activation against poliovirus receptor+ (PVR+) tumor cells and to synergize the therapeutic monoclonal antibodies (such as Rituximab) mediated ADCC activity. Combining this with the ability of Tislelizumab to rescue functionally “exhausted” T cells and the chemotherapy when R-CHOP is indicated (cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride) , vincristine (Oncovin) and prednisone) , this combination can have the ability to address aggressive forms of DLBCL or R/R DLBCL.
Claims (30)
- A method of diffuse large B-cell lymphoma (DLBCL) treatment, the method comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-PD1 antibody or antigen binding fragment thereof.
- The method of claim 1, wherein the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
- The method of claim 2, wherein the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
- The method of claim 1, wherein the anti-PD1 antibody comprises an antibody or an antigen binding fragment thereof which specifically binds human PD1, and comprises:a heavy chain variable region that comprises: a HCDR1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14; and a light chain variable region that comprises LCDR1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17.
- The method of claim 4, wherein the anti-PD1 antibody or antigen binding fragment thereof which specifically binds human PD1 and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 18 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 19.
- The method of claim 4 or 5 wherein the anti-PD1 antibody comprises an IgG4 constant domain comprising SEQ ID NO: 20.
- The method of claim 1, wherein the anti-TIGIT antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab') 2 fragments.
- The method of claim 1, wherein the anti-PD1 antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab') 2 fragments.
- A method of diffuse large B-cell lymphoma (DLBCL) treatment, the method comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-CD20 antibody or antigen binding fragment thereof.
- The method of claim 9, wherein the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
- The method of claim 10, wherein the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
- The method of claim 9, wherein the anti-CD20 antibody is Rituximab (Rituxan) , Britumomab (Zevalin) , Tositumomab (Bexxar) or Obinutuzumab (Gazyva) .
- The method of claim 12, wherein the anti-CD20 antibody is Rituximab (Rituxan) .
- The method of claim 1 or claim 9, wherein the DLBCL is relapsed or refractory DLBCL.
- The method of claim 1 or claim 9 further comprising the administration of chemotherapy.
- The method of claim 15, wherein the chemotherapy is cyclophosphamide, doxorubicin, vincristine, and prednisone.
- The method of claim 1, wherein the anti-PD1 antibody is dosed at 200mg every three weeks.
- The method of claim 1, wherein the anti-TIGIT antibody is dosed at a range of 50mg-900mg.
- The method of claim 1, wherein the anti-TIGIT antibody is dosed at 50 mg every three weeks.
- The method of claim 1, wherein the anti-TIGIT antibody is dosed at 150 mg every three weeks.
- The method of claim 1, wherein the anti-TIGIT antibody is dosed at 450 mg every three weeks.
- The method of claim 1, wherein the anti-TIGIT antibody is dosed at 900 mg every three weeks.
- The method of claim 13, wherein Rituxan is administered at 375 mg/m2.
- A method of diffuse large B-cell lymphoma (DLBCL) treatment, the method comprising administering to a subject an effective amount of an anti-TIGIT antibody or antigen-binding fragment thereof in combination with an effective amount of an anti-CD20 antibody or antigen binding fragment thereof and an effective amount of an anti-PD1 antibody.
- The method of claim 24, wherein the method comprises administering to a subject an effective amount of an antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6.
- The method of claim 25, wherein the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
- The method of claim 24, wherein the anti-PD1 antibody comprises an antibody or an antigen binding fragment thereof which specifically binds human PD1, and comprises:a heavy chain variable region that comprises: a HCDR1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14; and a light chain variable region that comprises LCDR1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17.
- The method of claim 27, wherein the anti-PD1 antibody or antigen binding fragment thereof which specifically binds human PD1 and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 18 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 19.
- The method of claim 24 further comprising the administration of chemotherapy.
- The method of claim 29, wherein the chemotherapy is cyclophosphamide, doxorubicin, vincristine, and prednisone.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2022/099068 | 2022-06-16 | ||
CN2022099068 | 2022-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023241659A1 true WO2023241659A1 (en) | 2023-12-21 |
Family
ID=89192316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/100462 WO2023241659A1 (en) | 2022-06-16 | 2023-06-15 | Methods of treating lymphoma using anti-tigit antibodies |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023241659A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020009444A1 (en) * | 2000-04-25 | 2002-01-24 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
WO2015035606A1 (en) * | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
WO2019129261A1 (en) * | 2017-12-30 | 2019-07-04 | Beigene, Ltd. | Anti-tigit antibodies and their use as therapeutics and diagnostics |
-
2023
- 2023-06-15 WO PCT/CN2023/100462 patent/WO2023241659A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020009444A1 (en) * | 2000-04-25 | 2002-01-24 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
WO2015035606A1 (en) * | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
WO2019129261A1 (en) * | 2017-12-30 | 2019-07-04 | Beigene, Ltd. | Anti-tigit antibodies and their use as therapeutics and diagnostics |
Non-Patent Citations (3)
Title |
---|
JOHNSON P W M ET AL: "Rituximab: Mechanisms and applications", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP UK, LONDON, vol. 85, no. 11, 30 November 2001 (2001-11-30), London, pages 1619 - 1623, XP002342924, ISSN: 0007-0920, DOI: 10.1054/bjoc.2001.2127 * |
SUNSERI, N. ET AL: "Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL", BLOOD, vol. 134, no. S1, 13 November 2019 (2019-11-13), XP086670235, DOI: 10.1182/blood-2019-131493 * |
SZYDŁOWSKI MACIEJ, GARBICZ FILIP, JABŁOŃSKA EWA, GÓRNIAK PATRYK, KOMAR DOROTA, PYRZYŃSKA BEATA, BOJARCZUK KAMIL, PROCHOREC-SOBIESZ: "Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 81, no. 23, 1 December 2021 (2021-12-01), US, pages 6029 - 6043, XP093117331, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-21-1023 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3092456C (en) | Anti-tigit antibody and use thereof | |
KR101276513B1 (en) | Antibodies against insulin-like growth factor i receptor and uses thereof | |
KR20160126026A (en) | Combination therapies with anti-cd38 antibodies | |
WO2019223733A1 (en) | Anti-ox40 antibodies and methods of use | |
US20240026005A1 (en) | Anti-human pd-l2 antibodies | |
WO2021098757A1 (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies | |
KR20220151195A (en) | Anti-CD36 antibodies and their use to treat cancer | |
WO2023241659A1 (en) | Methods of treating lymphoma using anti-tigit antibodies | |
WO2021098769A1 (en) | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors | |
TW202408571A (en) | Methods of treating lymphoma using anti-tigit antibodies | |
WO2022156726A1 (en) | Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies | |
WO2024041651A1 (en) | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies | |
WO2021098774A1 (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies | |
WO2024012584A1 (en) | Methods of cancer treatment using anti-tigit antibodies | |
WO2021098758A1 (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies | |
WO2021098749A1 (en) | Methods of cancer treatment with anti-ox40 antibody in combination with radiation | |
WO2024044675A1 (en) | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23823225 Country of ref document: EP Kind code of ref document: A1 |